Reported Earlier, Precigen Prices $30M Public Offering Of 35,294,118 Common Stock At $0.85/Share
Reported Earlier, Precigen Prices $30M Public Offering Of 35,294,118 Common Stock At $0.85/Share
據報道，Precigen以每股0.85美元的價格定價了3500萬股普通股的公開發行。
Precigen intends to use the net proceeds from the offering for advancing PRGN-2012 to regulatory approval and commercial readiness, limited clinical development of other pipeline assets, and for working capital and general corporate purposes. The net proceeds of the offering, together with Precigen's recently announced strategic reprioritization and streamlining of resources and cash on hand, are expected to fund Precigen's operations into early 2025.
Precigen擬將此次募集資金（淨額）用於推進PRGN-2012的監管批准和商業準備、少量其他流水線資產的臨床開發以及流動資本和一般公司用途。此次發行的淨收益與Precigen最近宣佈的戰略重組和現金措施相結合，預計將資助Precigen運營至2025年初。